Cover Image
市場調查報告書

視網膜胚細胞瘤治療的全球市場:2015-2019年

Global Retinoblastoma Treatment Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336937
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
視網膜胚細胞瘤治療的全球市場:2015-2019年 Global Retinoblastoma Treatment Market 2015-2019
出版日期: 2015年08月05日 內容資訊: 英文 62 Pages
簡介

全球視網膜胚細胞瘤治療的市場預計從2014年到2019年以3.57%的年複合成長率擴大。

本報告提供全球視網膜胚細胞瘤治療的市場相關調查、視網膜胚細胞瘤概要、診斷、管理、治療方法、開發平台趨勢、藥物類別種類與概要、市場規模的變化與預測、各地區的趨勢、市場成長的各種影響因素分析、競爭環境與市場佔有率、主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 簡稱

第3章 調查範圍

  • 市場概要
  • 主要的提供產品

第4章 市場調查手法

第5章 簡介

第6章 疾病概要

  • 關於疾病
  • 原因
  • 分類
    • 兩側性視網膜胚細胞瘤
    • 一側性視網膜胚細胞瘤
  • 症狀
  • 診斷
    • 患者的體檢
    • 影像檢查
    • 切片檢查
    • 臨床檢驗
  • 流行病學
  • 癌症分期
    • 眼球內
    • 眼球外
  • 管理
    • 寒冷療法
    • 化療
    • 光凝固
    • 放射線治療
    • 外科手術
    • 溫熱療法

第7章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第8章 開發平台分析

  • 開發平台候補的主要資訊
    • NTX-010
    • Racotumomab
    • Kevetrin
    • BL-8040
    • Melphalan
    • 視網膜胚細胞瘤RNAioligo核苷酸

第9章 各類藥物市場

  • 烷化劑
  • 代謝拮抗劑
  • 微管抑制劑
  • 細胞毒性抗生劑
  • 異構轉化酶抑制劑
  • 其他

第10章 各疾病狀態市場

第11章 地區分析

第12章 購買標準

第13章 市場成長因素

第14章 成長因素與其影響

第15章 市場課題

第16章 成長因素與課題的影響

第17章 市場趨勢

第18章 市場趨勢與其影響

第19章 供應商環境

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Baxter
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Spectrum Pharmaceuticals
  • 其他的有力供應商

第20章 主要供應商分析

  • Baxter International Inc.
  • Bristol-Myers Squibb
  • GlaxoSmithKline
    • 產業概要
    • 各產業收益
    • 各地區收益
    • 產業策略
    • 近幾年的發展趨勢
    • SWOT分析等

圖表

目錄
Product Code: IRTNTR6804

About retinoblastoma

Cancer occurs when normal cells transform to evade the regular cell cycle process. Retinoblastoma is a rare eye cancer. It occurs in children of age less than 15 years; the disease is common in children younger than five years, especially children less than two years. The disease affects the retina and is caused by a mutation in the gene RB1. It usually appears in one eye and gradually spreads to the other. Clinically, retinoblastoma is classified into two: unilateral retinoblastoma, tumor in one eye, and bilateral retinoblastoma, tumor in both the eyes.

Technavio's analysts forecast the global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma.

Technavio's report, Global Retinoblastoma Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the market segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Baxter
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Spectrum Pharmaceuticals

Other Prominent Vendors

  • BioLineRx
  • Cellceutix
  • Icon Bioscience
  • Neotropix
  • RXi Pharmaceuticals
  • Recombio

Key market driver

  • Increasing public awareness
  • For a full, detailed list, view our report

Key market challenge

  • Treatment abandonment
  • For a full, detailed list, view our report

Key market trend

  • Localized treatment approach
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology
  • 06.3. Classification
    • 06.3.1. Bilateral Retinoblastoma
    • 06.3.2. Unilateral Retinoblastoma
  • 06.4. Symptoms
  • 06.5. Diagnosis
    • 06.5.1. Patient Examination
    • 06.5.2. Imaging Tests
    • 06.5.3. Biopsy Tests
    • 06.5.4. Clinical Tests
  • 06.6. Epidemiology
  • 06.7. Staging
    • 06.7.1. Intraocular Staging
    • 06.7.2. Extraocular staging
  • 06.8. Management
    • 06.8.1. Cryotherapy
    • 06.8.2. Chemotherapy
    • 06.8.3. Photocoagulation
    • 06.8.4. Radiation therapy
    • 06.8.5. Surgery
    • 06.8.6. Thermo therapy

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Pipeline Analysis

  • 08.1. Key Information of the Pipeline Candidates
    • 08.1.1. NTX-010
    • 08.1.2. Racotumomab
    • 08.1.3. Kevetrin
    • 08.1.4. BL-8040
    • 08.1.5. Melphalan
    • 08.1.6. RNAi Oligonucleotide for Retinoblastoma

09. Market Segmentation by Therapeutic Class of Drugs

  • 09.1. Alkylating Agents
  • 09.2. Antimetabolites
  • 09.3. Microtubule Inhibitors
  • 09.4. Cytotoxic Antibiotics
  • 09.5. Topoisomerase Inhibitors
  • 09.6. Others

10. Market Segmentation by Disease Status

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Baxter
    • 19.2.2. Bristol-Myers Squibb
    • 19.2.3. GlaxoSmithKline
    • 19.2.4. Spectrum Pharmaceuticals
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Baxter International Inc.
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Business Segmentation
    • 20.1.4. Business Strategy
    • 20.1.5. Revenue by Business Segmentation
    • 20.1.6. Revenue by Geographical Segmentation
    • 20.1.7. Key Developments
    • 20.1.8. SWOT Analysis
  • 20.2. Bristol-Myers Squibb
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Key Product Offerings
    • 20.2.4. Revenue by Geography
    • 20.2.5. Business Strategy
    • 20.2.6. Key Information
    • 20.2.7. SWOT Analysis
  • 20.3. GlaxoSmithKline
    • 20.3.1. Business Overview
    • 20.3.2. Business Segmentation
    • 20.3.3. Business Segmentation by Revenue 2012 and 2013
    • 20.3.4. Sales by Geography
    • 20.3.5. Key Facts
    • 20.3.6. Pipeline Products
    • 20.3.7. Business Strategy
    • 20.3.8. Key Information
    • 20.3.9. SWOT Analysis

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Classification of Retinoblastoma
  • Exhibit 3: Symptoms: Percentage Occurrence in Patients
  • Exhibit 4: Techniques Used for Diagnosing Retinoblastoma
  • Exhibit 5: Intraocular Staging
  • Exhibit 6: Extraocular Staging
  • Exhibit 7: Retinoblastoma: Treatment Options
  • Exhibit 8: Global Retinoblastoma Market 2014-2019 (US$ million)
  • Exhibit 9: Pipeline Portfolio
  • Exhibit 10: Global Retinoblastoma Market by Therapeutic Class of Drugs
  • Exhibit 11: Global Retinoblastoma Market by Disease Status
  • Exhibit 12: Global Retinoblastoma Market: Percentage Share of Cases (2014)
  • Exhibit 13: Global Retinoblastoma Market by Geographical Segmentation 2014
  • Exhibit 14: Baxter
  • Exhibit 15: Bristol Myers-Squibb
  • Exhibit 16: GlaxoSmithKline
  • Exhibit 17: Spectrum Pharmaceuticals
  • Exhibit 18: Baxter International Inc. : Business Segmentation
  • Exhibit 19: Baxter International Inc.: Revenue by Business Segmentation 2013
  • Exhibit 20: Baxter International Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 21: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 22: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 23: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 24: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 25: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 26: GlaxoSmithKline: Pipeline Products 2013
Back to Top